Patients with stage IIIB/IV disease stratified by adjuvant therapy and gender were randomised @ : @ to axitinib ( @ mg twice daily ) or bevacizumab -LSB- @ mg/kg every @ weeks ( Q@W ) -RSB- , both with paclitaxel ( @ mg/m ( @ ) Q@W ) / carboplatin ( AUC @ mg min/ml Q@W ) .